DOM: The impact of suboptimal control of type 2 diabetes on the public economic burden on taxpayers in Sweden

Objective: To assess the financial burden on Swedish taxpayers of patients with type 2 diabetes (T2D) due to diabetes-related complications who fail to meet the HbA1c target

To assess the financial burden on Swedish taxpayers of patients with type 2 diabetes (T2D) who fail to meet glycated hemoglobin targets due to diabetes-related complications

RESULTS: The 10-year estimated per capita income loss for direct and delayed control of HbA1c was SEK42,299 and SEK44,157, respectively

Table 1 Financial impact of 3-year delayed glycemic control on each patient in people aged ≤65 years, with a baseline HbA1c of 6.

Table 1 Financial impact of 3-year delayed glycemic control on each patient in people aged ≤65 years, with a baseline HbA1c of 6.

Table 2.

Table 2.

Figure 1 Fiscal model design; Abbreviations: IHD ischemic heart disease; Myocardial infarction: myocardial infarction; Yes: ischemic stroke; CHF: Coronary heart failure; No Ret: No retinopathy; BDR: Background diabetic retinopathy; PDR: proliferative diabetic retinopathy; I: macular edema; SVL: severe vision loss; No Neur: no neurological complications; Symptoms: symptomatic neurological complications; PVD: peripheral vascular disease: LEA EV: lower limb amputation extracellular vesicles; LEA HIST: history of lower extremity amputation; no kidney: no renal complications; MicroALB: Microalbinuria; MacroALB: Macroalbuminuria; end-stage renal disease

Figure 1 Fiscal model design; Abbreviations: IHD ischemic heart disease; Myocardial infarction: myocardial infarction; Yes: ischemic stroke; CHF: Coronary heart failure; No Ret: No retinopathy; BDR: Background diabetic retinopathy; PDR: proliferative diabetic retinopathy; I: macular edema; SVL: severe vision loss; No Neur: no neurological complications; Symptoms: symptomatic neurological complications; PVD: peripheral vascular disease: LEA EV: lower limb amputation extracellular vesicles; LEA HIST: history of lower extremity amputation; no kidney: no renal complications; MicroALB: Microalbinuria; MacroALB: Macroalbuminuria; end-stage renal disease

We demonstrate that a fiscal analysis of diabetes interventions provides a rich perspective that captures a range of costs for governments in terms of lost tax revenue and disability compensation

The public economic burden of sub-optimal type-2 diabetes control on tax payors in Sweden: Looking beyond health costs.


Leave a comment here